Details of Drug-Drug Interaction
| Drug General Information (ID: DDIMO69QXU) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Lapatinib | Drug Info | Dexlansoprazole | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antineoplastics | Proton Pump Inhibitors | |||||||
| Structure | |||||||||
| Mechanism of Lapatinib-Dexlansoprazole Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered gastric pH Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Lapatinib | Dexlansoprazole | |||||||
| Mechanism | Gastric pH sensitive | Gastric alkalinizer | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Gastric pH | ||||||||
| Factor Description | The normal pH range of gastric acid is between 1.5 and 3.5 and is highly acidic, consisting mainly of hydrochloric acid. Changes in the pH of the stomach can alter the absorption of drugs. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution may be advisable if lapatinib is used in combination with H2-receptor antagonists or proton pump inhibitors. Patients should be monitored for potentially reduced therapeutic response to lapatinib. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||||||||||||||||